RAPT - RAPT Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
25.46
-1.03 (-3.89%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close26.49
Open26.48
Bid24.00 x 900
Ask25.50 x 900
Day's Range25.34 - 27.27
52 Week Range10.52 - 51.21
Volume112,102
Avg. Volume142,000
Market Cap620.554M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.70
Earnings DateMay 14, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Insider Buying: Wendye Robbins Just Spent US$68k On RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares
    Simply Wall St.

    Insider Buying: Wendye Robbins Just Spent US$68k On RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares

    Even if it's not a huge purchase, we think it was good to see that Wendye Robbins, a RAPT Therapeutics, Inc...

  • GlobeNewswire

    Peter Svennilson Elected to RAPT Therapeutics Board of Directors

    Mr. Svennilson will replace David Goeddel, Ph.D., who did not stand for reelection to RAPT’s Board of Directors due to other responsibilities, but will remain a member of RAPT’s Scientific Advisory Board (SAB). “Peter has been integrally involved with RAPT over the course of the last several years, helping to steer our strategic direction and expanding our network within the industry, and we welcome his consistent counsel as an active Board member moving forward,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics.

  • GlobeNewswire

    RAPT Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., June 17, 2020 -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering,.

  • RAPT Therapeutics, Inc. (NASDAQ:RAPT) Analysts Just Trimmed Their Revenue Forecasts By 12%
    Simply Wall St.

    RAPT Therapeutics, Inc. (NASDAQ:RAPT) Analysts Just Trimmed Their Revenue Forecasts By 12%

    The latest analyst coverage could presage a bad day for RAPT Therapeutics, Inc. (NASDAQ:RAPT), with the analysts...

  • GlobeNewswire

    RAPT Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Virtual Scientific Program

    The poster was presented at the American Society of Clinical Oncology (ASCO) 2020. The poster presentation detailed previously reported initial Phase 1 healthy volunteer data for FLX475 that demonstrated excellent safety, pharmacokinetics (PK) and target engagement. FLX475 is designed to block regulatory T cells from migrating to tumor sites, where they suppress immune system responses to cancer cells, without depleting regulatory T cells in the rest of the body nor immune cells required for an anti-tumor response.

  • GlobeNewswire

    RAPT Therapeutics to Present at the Jefferies Virtual Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., May 26, 2020 -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering,.

  • Revenue Downgrade: Here's What Analysts Forecast For RAPT Therapeutics, Inc. (NASDAQ:RAPT)
    Simply Wall St.

    Revenue Downgrade: Here's What Analysts Forecast For RAPT Therapeutics, Inc. (NASDAQ:RAPT)

    Today is shaping up negative for RAPT Therapeutics, Inc. (NASDAQ:RAPT) shareholders, with the analysts delivering a...

  • RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Reported And Analysts Have Been Cutting Their Estimates
    Simply Wall St.

    RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Reported And Analysts Have Been Cutting Their Estimates

    RAPT Therapeutics, Inc. (NASDAQ:RAPT) missed earnings with its latest first-quarter results, disappointing...

  • Read This Before Selling RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares
    Simply Wall St.

    Read This Before Selling RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • GlobeNewswire

    RAPT Therapeutics Highlights Early Results for RPT193 at Society for Investigative Dermatology Meeting

    SOUTH SAN FRANCISCO, Calif., May 15, 2020 -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering,.

  • GlobeNewswire

    RAPT Therapeutics Reports First Quarter 2020 Financial Results

    SOUTH SAN FRANCISCO, Calif., May 14, 2020 -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering,.

  • GlobeNewswire

    RAPT Therapeutics to Present at the UBS Virtual Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., May 12, 2020 -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering,.

  • GlobeNewswire

    RAPT Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif., March 30, 2020 -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering,.

  • GlobeNewswire

    RAPT Therapeutics Announces Management Promotions

    RAPT Therapeutics, Inc. (RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the promotions of Paul Kassner, Ph.D., to Senior Vice President of Quantitative and Computational Biology and Lisa Moore, Ph.D., to Vice President of Business Development and Strategy. “Both Paul and Lisa continue to make incredible contributions to RAPT’s success in setting and implementing strategic business and scientific plans,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics.

  • GlobeNewswire

    RAPT Therapeutics Announces Upcoming Investor Conference Presentations

    SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering,.

  • GlobeNewswire

    RAPT Therapeutics Announces Pricing of $75 Million Public Offering

    RAPT Therapeutics, Inc. (RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the pricing of its underwritten public offering of 2,500,000 shares of common stock at a public offering price of $30.00 per share. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 375,000 shares of common stock at the public offering price, less the underwriting discount. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by RAPT, are expected to be $75.0 million, excluding any exercise of the underwriters’ option to purchase additional shares.

  • GlobeNewswire

    RAPT Therapeutics Announces Proposed Offering of Common Stock

    RAPT Therapeutics, Inc. (RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that it has commenced an underwritten public offering of 2,000,000 shares of its common stock. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock sold in connection with the offering. BMO Capital Markets, Wells Fargo Securities, UBS Investment Bank and Cantor Fitzgerald & Co. are acting as joint book-running managers for the offering.

  • We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
    Simply Wall St.

    We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

  • GlobeNewswire

    RAPT Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering,.

  • GlobeNewswire

    RAPT Therapeutics to be Added to the Russell 2000® and Russell Microcap® Indices

    RAPT Therapeutics, Inc. (RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that the Company will be added to the Russell 2000® and Russell Microcap® Indices as a part of the Russell quarterly update, effective December 23, 2019. The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market, while membership in the Russell Microcap® Index measures the performance of the micro-cap segment. Membership in the Russell 2000 and Microcap Indices also provides automatic inclusion in the appropriate growth and value style indices.

  • GlobeNewswire

    RAPT Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights

    SOUTH SAN FRANCISCO, Calif., Dec. 11, 2019 -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering,.

  • GlobeNewswire

    RAPT Therapeutics Appoints Mary Ann Gray, Ph.D., to Board of Directors

    RAPT Therapeutics, Inc. (RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Mary Ann Gray, Ph.D., President of Gray Strategic Advisors, LLC, has joined its Board of Directors. “We are pleased to welcome Mary Ann to our Board, as she brings a wealth of scientific and financial expertise from her time investing in and covering biotech companies, as well as broad leadership experience guiding companies as they develop key therapeutics with a wide range of pharmacological applications,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics.

  • GlobeNewswire

    RAPT Therapeutics Appoints Rodney Young as Chief Financial Officer

    RAPT Therapeutics, Inc. (RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the appointment of Rodney Young as chief financial officer effective December 2, 2019. “As a newly public company, we are thrilled to welcome Rodney to RAPT,” said Brian Wong, M.D., Ph.D., president and CEO of RAPT Therapeutics. Mr. Young brings more than 30 years of executive management and corporate finance experience.

  • Benzinga

    The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares ...

  • GlobeNewswire

    RAPT Therapeutics and Hanmi Pharmaceutical Announce Collaboration to Develop and Commercialize FLX475 in Asia

    RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, and Hanmi Pharmaceutical Co., LTD today announced a license and collaboration agreement for FLX475 in Asia. FLX475 is an oral, small molecule CCR4 antagonist in development for the treatment of multiple cancers.